

Final - October 27, 2020

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

October 28-30, 2020

<u>AGENDA ITEM</u>	<u>PRESIDER/PRESENTER(s)</u>
Wednesday, October 28, 2020	
10:00 Welcome & Introductions	Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
10:30 Immunization Schedules	
Introduction to combined immunization schedule work group	Dr. Hank Bernstein (ACIP, WG Co-Chair) Dr. Kevin Ault (ACIP, WG Co-Chair)
Proposed changes to 2021 child/adolescent immunization schedule	Dr. Patricia Wodi (CDC/NCIRD)
Proposed changes to 2021 adult immunization schedule	Dr. Mark Freedman (CDC/NCIRD)
11:30 Break	
11:45 Seasonal Influenza Vaccines	
Introduction	Dr. Keipp Talbot (ACIP, WG Chair)
Efficacy of cell-derived quadrivalent influenza vaccine (Flucelvax Quadrivalent) in children & adolescents ≥ 2 years to < 18 years old	Dr. Gregg Sylvester (Seqirus)
Influenza Disease Burden and Vaccine Impact Estimates, 2019-20 Season	Dr. Carrie Reed (CDC/NCIRD)
End-of-Season Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness against Medically Attended Influenza from three U.S. Networks	Dr. Lisa Grohskopf (CDC/NCIRD)
Updates and WG Considerations	Dr. Lisa Grohskopf (CDC/NCIRD)
12:30 Lunch	
1:15 Orthopoxvirus Vaccine	
Introduction	Dr. Beth Bell (ACIP, WG Chair)
Orthopoxvirus work group background	Dr. Brett Petersen (CDC/NCEZID)
JYNNEOS® (MVA-BN®) Smallpox and Monkeypox Vaccine	Dr. Heinz Weidenthaler (Bavarian Nordic)
Variola virus plaque reduction neutralization assay for the Vaccinating against monkeypox in the Democratic Republic of the Congo with JYNNEOS®	Dr. Christina Hutson (CDC/NCEZID) Dr. Brett Petersen (CDC/NCEZID)
Next Steps	Dr. Agam Rao (CDC/NCEZID)
2:45 Break	
2:55 Dengue Vaccines	
Introduction	Dr. Robert Atmar (ACIP, WG Chair)
3:05 Pneumococcal Vaccines	
Work group introduction	Dr. Katherine Poehling (ACIP, WG Chair) Dr. Miwako Kobayashi (CDC/NCIRD)
3:15 Cholera Vaccines	
Work group introduction	Dr. Pablo Sanchez (ACIP, WG Chair)
3:25 Break	
3:30 Public Comment	
4:15 Break	
4:20 Vote - Immunization Schedules	Dr. Mark Freedman (CDC/NCIRD)
4:30 Adjourn	

Final - October 27, 2020

Thursday, October 29, 2020

10:00	Unfinished Business and Agency Updates CDC, CMS, FDA, HRSA, IHS, NIH, ODP	
10:15	Zoster Vaccine Introduction Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix) in the Vaccine Adverse Event Reporting System (VAERS) Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of RZV Risk of Guillain-Barré syndrome following herpes zoster Summary and planned risk-benefit analysis regarding use of RZV in immunocompetent adults Planned risk-benefit analysis regarding use of RZV in immunocompetent adults	Dr. Grace Lee (ACIP, WG Chair) Dr. John Su (CDC/NCEZID) Dr. Jennifer Nelson (Kaiser Permanente) Dr. Tara Anderson (CDC/NCIRD) Dr. Tara Anderson (CDC/NCIRD) Dr. Tara Anderson (CDC/NCIRD)
11:45	Lunch	
12:20	Tick-borne Encephalitis Vaccine Introduction Overview of tick-borne encephalitis (TBE) and TBE vaccine Immunogenicity and safety of Pfizer's TBE vaccine Next steps for TBE vaccine work group	Dr. Katherine Poehling (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Dr Heinz-Joseph Schmitt (Pfizer) Dr. Susan Hills (CDC/NCEZID)
2:00	Break	
2:15	Rabies Vaccine Introduction Minimum acceptable rabies antibody titer and implications on ACIP recommendations Pertinent fundamentals of rabies immunology	Dr. Sharon Frey (ACIP, WG Chair) Dr. Susan Moore (Kansas State University) Dr. Deborah Briggs (Kansas State University)
3:30	Break Pre-exposure prophylaxis schedule: Grading of recommendations assessment, development, and evaluation (GRADE) Evidence to recommendation framework (EtR) Summary and next steps	Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID)
4:50	Adjourn	

Final - October 27, 2020

Friday, October 30, 2020

10:00	Coronavirus Disease 2019 (COVID-19) Vaccines	
	Introduction	Dr. Beth Bell (ACIP, WG Chair)
	Update from Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting	Dr. Doran Fink (FDA)
	NVX-CoV2373 Vaccine Candidate	Dr. Filip Dubovsky (Novavax)
	Janssen's SARS-CoV-2 Vaccine Program	Dr. Jerry Sadoff (Janssen)
11:45	Break	
12:00	Update on vaccine implementation planning	Dr. Janell Routh (CDC/NCIRD)
	Vaccinate with Confidence	Dr. Amanda Cohn (CDC/NCIRD)
12:30	Lunch	
1:15	FDA safety surveillance systems	Dr. Steven Anderson (FDA)
	Post-authorization safety monitoring plans	Dr. Tom Shimabukuro (CDC/NCEZID)
	Modeling strategies for the initial allocation of COVID-19 vaccines	Dr. Matthew Biggerstaff (CDC/NCIRD)
	Discussion	
2:30	Break	
2:45	Updates to immunity and epidemiology to inform COVID-19	Dr. Megan Wallace (CDC/NCIRD)
	Ethical principles for early vaccine allocation	Dr. Mary Chamberland (CDC/NCIRD)
	Work Group interpretation of data	Dr. Sara Oliver (CDC/NCIRD)
	Policy questions, Evidence to Recommendation Framework, and Discussion	Dr. Kathleen Dooling (CDC/NCIRD)
4:45	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus Disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
RZV	Recombinant Zoster Vaccine
SAGE	Strategic Advisory Group of Experts
SARS-CoV-2	Severe Acute Respiratory Syndrome coronavirus 2
WG	Work Group
WHO	World Health Organization
VAERS	Vaccine Adverse Event Reporting System
VE	Vaccine Effectiveness